MAM
Chitralekha adds seven new marketing categories in Watch Awards
NEW DELHI: Seven marketing categories have been included in the sixth edition of the annual Watch Awards this year. Hosted by the Chitralekha Group, the Watch World Awards 2015 will be held on 9 October at the Westin Gurgaon.
The event will see top-end luxury watch brands vying for the coveted awards in multiple categories.
The marketing awards include Best Campaigns in Print and TV, Best Use of Ambient Media, Best Boutique, Best Organised Event and Best Integrated Marketing Campaign. This year sees the introduction of a new marketing category, Best use of Social Media, which will reward brands with most effective and innovative social media strategy.
Filmmaker Apoorva Lakhia was a member of the four-member jury that judged the product category. Senior marketing & business transformation specialist (automotive & retail) Nitish Tipnis judged the marketing category.
Elaborating on the sixth edition of Watch World Awards, Chitralekha Group president and publisher Mitrajit Bhattacharya said, “Watch World Awards has gathered a stature, which the watch industry looks forward to. With each edition, the list of marquee brands has grown up reiterating the significance of the unique platform we have created. Most importantly the awards have been able to touch the right chord with the watch brands and watch lover. Like earlier years, this year too we have put up an incredible jury hailing from watch-making, design, sports, collaborative art and marketing. The sixth edition is going to be exciting enough as we have received a remarkable response from top-notch watch brands.”
Expected attendees include Bollywood actors Yami Gautam, Nimrat Kaur and Pallavi Sharda amongst others.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
